Milestone Pharma reports FY2021 net loss of $42.9M; revenue of $15M from collaboration

Milestone Pharmaceuticals Inc.

Net loss for FY2021 was $42.9M ($1.02 loss per share) vs $50.0M ($1.70 loss per share) in FY2020.
Revenue of $15.0M recognized in 2021 from collaboration agreement; no revenue in 2020.
R&D expenses $38.7M, G&A $12.4M, commercial $7.0M in FY2021.
Cash and cash equivalents $114.1M at Dec 31, 2021, down from $142.3M (incl short-term investments) at Dec 31, 2020.
Accumulated deficit reached $206.3M as of Dec 31, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.